A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

For new and old investors, taking full advantage of the stock market ... Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. AstraZeneca plc, headquartered ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

If an investor was to purchase shares of AZN stock at the current price level of $70.69/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Absci Corporation’s ABSI share price has surged by 17.57%, which has investors questioning if this is right time to sell.

Harvey Jones called on artificial intelligence to help him decide where to invest this year's Stocks and Shares ISA allowance ...

The average twelve-month target price among analysts that have issued a report on the stock in the last year is GBX 7,935.67 ($98.80). A number of brokerages recently weighed in on AZN.

Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $89.75. Shares of AstraZeneca stock opened at $71.24 on Friday. The firm ...